May 08, 2017
The Lancet Oncology: Safety and tolerability of the first-in-class agent CPI-613® in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial
Learn More >>

October 12, 2016
PLOS ONE: A Phase II Clinical Trial of CPI-613® in Patients with Relapsed or Refractory Small Cell Lung Carcinoma
Learn More >>

October 15, 2014
Clinical Cancer Research: A Phase I Study of the First-in-Class Antimitochondrial
Metabolism Agent,CPI-613®, in Patients with Advanced
Hematologic Malignancies
Learn More >>

Publications

May 08, 2017
The Lancet Oncology: Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial
Learn More >>

October 12, 2016
PLOS ONE: A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Small Cell Lung Carcinoma
Learn More >>

October 15, 2014
Clinical Cancer Research: A Phase I Study of the First-in-Class Antimitochondrial
Metabolism Agent, CPI-613, in Patients with Advanced
Hematologic Malignancies
Learn More >>